Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies-Reference-Cited by-同舟云学术

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies

Published:2019-06 Issue:4 Volume:154 Page:
ISSN:0392-0488
Container-title:Giornale Italiano di Dermatologia e Venereologia
language:
Short-container-title:G Ital Dermatol Venereol

Author:

Dousset Léa,Boniface Katia,Seneschal Julien

Publisher

Edizioni Minerva Medica

Subject

Dermatology

Link

https://www.minervamedica.it/pdf.php?cod=R23Y2019N04A0435

Reference75 articles.

1. Immunotherapy of autoimmunity and cancer: the penalty for success

2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

3. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

4. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

5. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials;Wolchok JD;Cancer Immun,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitiligo-Like Depigmentation Induced by Anti–Programmed Death 1 Antibody;Dermatitis®;2023-02-01

2. Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis;Scientific Reports;2022-11-21

3. Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study;Frontiers in Immunology;2022-08-26

4. Vitiligo-Like Depigmentation Induced by Anti–Programmed Death 1 Antibody;Dermatitis;2022-08-12

5. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study;JAAD International;2021-12